JP2000502672A - 生ワクチンの安定化剤 - Google Patents
生ワクチンの安定化剤Info
- Publication number
- JP2000502672A JP2000502672A JP09523371A JP52337197A JP2000502672A JP 2000502672 A JP2000502672 A JP 2000502672A JP 09523371 A JP09523371 A JP 09523371A JP 52337197 A JP52337197 A JP 52337197A JP 2000502672 A JP2000502672 A JP 2000502672A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- stabilizer
- vaccine
- stabilizer according
- blended
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0015—Combination vaccines based on measles-mumps-rubella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/20—Rubella virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16751—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18451—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18751—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.一種またはそれ以上の弱毒生ウイルスを含む組成物、特にワクチンのための 安定化剤であって、それぞれ以下の群: − アミノ酸、 − 二糖類、 − 多価アルコール および緩衝液 から選択される一つまたはそれ以上の成分(ただし、二糖類群から選択される成 分の一つはシュークロースである)を含むことを特徴とする安定化剤。 2.二糖類群から選択される成分(複数でも可)が2ないし6%の割合で配合さ れていることを特徴とする請求項1記載の安定化剤。 3.二糖類群から選択される成分(複数でも可)が2.5%の割合で配合されて いることを特徴とする請求項2記載の安定化剤。 4.多価アルコール群がソルビトールおよびマンニトールを包含することを特徴 とする、請求項1ないし3のいずれか一つに記載の安定化剤。 5.ソルビトールおよびマンニトールを含むことを特徴とする請求項4記載の安 定化剤。 6.ソルビトールが2ないし6%の割合で配合されている請求項4および5のい ずれかに記載の安定化剤。 7.ソルビトールが5%の割合で配合されている請求項6記載の安定化剤。 8.マンニトールが1ないし2.5%の割合で配合されている請求項4および5 のいずれかに記載の安定化剤。 9.マンニトールが2.5%の割合で配合されている請求項8記載の安定化剤。 10.緩衝液群がリン酸緩衝液およびエチレンジアミン四酢酸を包含することを 特徴とする、請求項1ないし9のいずれか一つに記載の安定化剤。 11.リン酸緩衝液を含むことを特徴とする請求項10記載の安定化剤。 12.デキストランを含む請求項1ないし11のいずれか一つに記載の安定化剤 。 13.デキストランが1ないし4%の割合で配合されている請求項12記載の安 定化剤。 14.デキストランが3%の割合で配合されている請求項13記載の安定化剤。 15.尿素、その誘導体の一つ、またはそれらの混合物を含む、請求項1ないし 14のいずれかひとつに記載の安定化剤。 16.尿素、その誘導体の一つ、またはそれらの混合物が、0.125ないし2 %の割合で配合されている請求項15記載の安定化剤。 17.尿素、その誘導体の一つ、またはそれらの混合物が、0.5%の割合で配 合されている請求項16記載の安定化剤。 18.pH7に調整されている請求項1ないし17のいずれか一つに記載の安定 化剤。 19.請求項1ないし18のいずれか一つに記載の安定化剤を含む、安定化され た、弱毒生ウイルスワクチン。 20.少なくとも一種のヘルペス科ウイルスを含む請求項19記載のワクチン。 21.ヘルペス科ウイルスに水痘ウイルス、サイトメガロウイルスおよび単純ヘ ルペスウイルスが含まれる、請求項20記載のワクチン。 22.水痘ウイルスを含む請求項21記載のワクチン。 23.パラミクソウイルス(モルビウイルス、ムンプス、1型、2型、3型およ び4型のパラインフルエンザ、および、ニューモウイルス)、トガウイルス(風 疹)、および、インフルエンザ(A、BおよびC)ウイルスから選択される少な くとも一種のウイルスを含む請求項19記載のワクチン。 24.麻疹、風疹およびムンプスウイルスを含む請求項23記載のワクチン。 25.弱毒生ウイルスを含有する安定化ワクチンの製造方法であって、該ワクチ ンの製造に用いられるウイルスを、好ましくは凍結乾燥段階の前に、請求項1な いし19のいずれか一つに記載の安定化剤の適量と接触させることを特徴とする 方法。 26.ウイルスを収集する前に安定化剤と接触させることを特徴とする、請求項 25記載の方法。 27.請求項19ないし24のいずれか一つに記載のワクチンの製造方法であっ て、該ワクチンの製造に用いられるウイルスを、好ましくは凍結乾燥段階の前に 、請求項1ないし19のいずれか一つに記載の安定化剤の適量と接触させること を特徴とする方法。 28.ウイルスを収集する前に安定化剤と接触させることを特徴とする、請求項 27記載の方法。 29.請求項1ないし18のいずれか一つに記載の安定化剤を含む、安定化組成 物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR95/15778 | 1995-12-22 | ||
FR9515778A FR2742756B1 (fr) | 1995-12-22 | 1995-12-22 | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
PCT/FR1996/002054 WO1997023238A1 (fr) | 1995-12-22 | 1996-12-20 | Stabilisants pour vaccins vivants |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000502672A true JP2000502672A (ja) | 2000-03-07 |
JP4020431B2 JP4020431B2 (ja) | 2007-12-12 |
Family
ID=9486181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52337197A Expired - Fee Related JP4020431B2 (ja) | 1995-12-22 | 1996-12-20 | 生ワクチンの安定化剤 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6231860B1 (ja) |
EP (1) | EP0869814B1 (ja) |
JP (1) | JP4020431B2 (ja) |
CN (1) | CN1263508C (ja) |
AT (1) | ATE299712T1 (ja) |
AU (1) | AU726630B2 (ja) |
CA (1) | CA2240541C (ja) |
DE (1) | DE69634960T2 (ja) |
DK (1) | DK0869814T3 (ja) |
ES (1) | ES2242201T3 (ja) |
FR (1) | FR2742756B1 (ja) |
HU (1) | HU227946B1 (ja) |
MX (1) | MX9804965A (ja) |
NO (1) | NO320958B1 (ja) |
NZ (1) | NZ324742A (ja) |
PT (1) | PT869814E (ja) |
WO (1) | WO1997023238A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005120579A1 (ja) * | 2004-06-14 | 2005-12-22 | Ishihara Sangyo Kaisha, Ltd. | 膜融合活性のある不活性化ウイルスエンベロープの凍結乾燥組成物 |
JP2007517888A (ja) * | 2004-01-15 | 2007-07-05 | インターベツト・インターナシヨナル・ベー・ベー | 非動物由来安定剤およびその製造方法 |
JP2008532977A (ja) * | 2005-03-08 | 2008-08-21 | インターベツト・インターナシヨナル・ベー・ベー | 化学的に定義された安定剤組成物 |
JP2009161538A (ja) * | 2001-03-05 | 2009-07-23 | Bayer Schering Pharma Ag | 顆粒球マクロファージ・コロニー刺激因子の安定性のある水溶液 |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141244B1 (en) * | 1992-03-02 | 2006-11-28 | Chiron Srl | Helicobacter pylori proteins useful for vaccines and diagnostics |
WO1997025429A1 (en) * | 1996-01-04 | 1997-07-17 | Rican Limited | Helicobacter pylori bacterioferritin |
US20080261289A1 (en) * | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
CA2320419C (en) * | 1998-02-17 | 2011-02-08 | Schering Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
CN1053590C (zh) * | 1998-10-19 | 2000-06-21 | 卫生部长春生物制品研究所 | 冻干甲型肝炎减毒活疫苗及其保护剂 |
US20050175629A1 (en) * | 2001-08-31 | 2005-08-11 | Giuseppe Del Giudice | Helicobacter pylori vaccination |
KR20030025480A (ko) * | 2001-09-21 | 2003-03-29 | 보령제약 주식회사 | 약독화 수두 생바이러스 백신용 무단백질 안정화제 |
AU2003225057A1 (en) * | 2002-04-19 | 2003-11-03 | The Regents Of The University Of Michigan | Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens |
RU2458125C2 (ru) | 2004-11-05 | 2012-08-10 | Веллстат Байолоджикс Корпорейшн | Способ стабилизации вируса ньюкаслской болезни для хранения в водном растворе и способ сохранения его стабильности |
WO2007027076A1 (es) * | 2005-09-01 | 2007-03-08 | Nuno Ayala Jose Luis | Formula estabilizadora de vacunas con antígenos vivos para su uso en sistemas de vacunación masiva |
SI2144998T1 (sl) * | 2007-04-06 | 2017-05-31 | Takeda Vaccines, Inc. | Postopki in sestavki za žive atenuirane viruse |
CA2716399C (en) | 2008-03-05 | 2020-07-21 | Pierre Chouvenc | Process for stabilizing an adjuvant containing vaccine composition |
EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
CN101407788B (zh) * | 2008-11-26 | 2012-01-11 | 中国兽医药品监察所 | 一种促进狂犬病病毒增殖的方法 |
US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
FR2960781B1 (fr) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue |
WO2012028315A1 (en) * | 2010-09-02 | 2012-03-08 | Sanofi Pasteur Sa | A stabilizer for the preparation of a dry polio injectable vaccine composition |
AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
KR102023207B1 (ko) | 2010-12-02 | 2019-11-25 | 온콜리틱스 바이오테크 인코포레이티드 | 동결건조 바이러스 제형 |
JP6041361B2 (ja) | 2011-08-12 | 2016-12-07 | メリアル インコーポレイテッド | 生物学的製品、特にはワクチンの真空保存 |
US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
CN105267971B (zh) * | 2014-08-13 | 2019-05-03 | 科兴(大连)疫苗技术有限公司 | 一种不含明胶和人血白蛋白的疫苗冻干保护剂 |
CN104984357B (zh) | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
US10722570B2 (en) * | 2015-11-27 | 2020-07-28 | Nitto Denko Corporation | Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation |
CN106063933B (zh) * | 2015-12-31 | 2020-01-07 | 武汉博沃生物科技有限公司 | 通用疫苗冻干保护剂及其应用 |
US20200308550A1 (en) | 2017-09-11 | 2020-10-01 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Tumor organoid model |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS577423A (en) * | 1980-06-13 | 1982-01-14 | Takeda Chem Ind Ltd | Frozen or freeze-dried live measles vaccine |
FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
JPS60193925A (ja) * | 1984-03-13 | 1985-10-02 | Chemo Sero Therapeut Res Inst | 凍結乾燥製剤化ワクチン |
JPS6314729A (ja) * | 1986-06-30 | 1988-01-21 | スミスクライン・バイオロジカルス・ソシエテ・アノニム | 生ワクチン用改良安定剤、その製造法およびそれを含有するワクチン |
DD299213A7 (de) * | 1988-05-04 | 1992-04-09 | Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De | Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung |
FR2633518B1 (fr) * | 1988-06-30 | 1991-03-22 | Merieux Inst | Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues |
-
1995
- 1995-12-22 FR FR9515778A patent/FR2742756B1/fr not_active Expired - Fee Related
-
1996
- 1996-12-20 US US09/091,542 patent/US6231860B1/en not_active Expired - Lifetime
- 1996-12-20 CN CNB961800399A patent/CN1263508C/zh not_active Expired - Fee Related
- 1996-12-20 PT PT96943170T patent/PT869814E/pt unknown
- 1996-12-20 AT AT96943170T patent/ATE299712T1/de active
- 1996-12-20 HU HU9903713A patent/HU227946B1/hu not_active IP Right Cessation
- 1996-12-20 DK DK96943170T patent/DK0869814T3/da active
- 1996-12-20 NZ NZ324742A patent/NZ324742A/en not_active IP Right Cessation
- 1996-12-20 DE DE69634960T patent/DE69634960T2/de not_active Expired - Lifetime
- 1996-12-20 AU AU11986/97A patent/AU726630B2/en not_active Ceased
- 1996-12-20 ES ES96943170T patent/ES2242201T3/es not_active Expired - Lifetime
- 1996-12-20 JP JP52337197A patent/JP4020431B2/ja not_active Expired - Fee Related
- 1996-12-20 CA CA002240541A patent/CA2240541C/en not_active Expired - Fee Related
- 1996-12-20 WO PCT/FR1996/002054 patent/WO1997023238A1/fr active IP Right Grant
- 1996-12-20 EP EP96943170A patent/EP0869814B1/fr not_active Expired - Lifetime
-
1998
- 1998-06-19 NO NO19982861A patent/NO320958B1/no not_active IP Right Cessation
- 1998-06-19 MX MX9804965A patent/MX9804965A/es not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009161538A (ja) * | 2001-03-05 | 2009-07-23 | Bayer Schering Pharma Ag | 顆粒球マクロファージ・コロニー刺激因子の安定性のある水溶液 |
JP2007517888A (ja) * | 2004-01-15 | 2007-07-05 | インターベツト・インターナシヨナル・ベー・ベー | 非動物由来安定剤およびその製造方法 |
WO2005120579A1 (ja) * | 2004-06-14 | 2005-12-22 | Ishihara Sangyo Kaisha, Ltd. | 膜融合活性のある不活性化ウイルスエンベロープの凍結乾燥組成物 |
US8043610B2 (en) | 2004-06-14 | 2011-10-25 | Ishihara Sangyo Kaisha, Ltd. | Freeze-dried composition of inactivated virus envelope with membrane fusion activity |
JP2008532977A (ja) * | 2005-03-08 | 2008-08-21 | インターベツト・インターナシヨナル・ベー・ベー | 化学的に定義された安定剤組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN1209067A (zh) | 1999-02-24 |
DE69634960T2 (de) | 2006-03-30 |
EP0869814A1 (fr) | 1998-10-14 |
NZ324742A (en) | 1999-09-29 |
HU227946B1 (en) | 2012-06-28 |
CN1263508C (zh) | 2006-07-12 |
DK0869814T3 (da) | 2005-10-17 |
MX9804965A (es) | 1998-09-30 |
AU1198697A (en) | 1997-07-17 |
FR2742756B1 (fr) | 1998-04-03 |
JP4020431B2 (ja) | 2007-12-12 |
US6231860B1 (en) | 2001-05-15 |
FR2742756A1 (fr) | 1997-06-27 |
CA2240541A1 (en) | 1997-07-03 |
NO982861L (no) | 1998-06-19 |
NO982861D0 (no) | 1998-06-19 |
ES2242201T3 (es) | 2005-11-01 |
HUP9903713A2 (hu) | 2000-03-28 |
HUP9903713A3 (en) | 2001-10-29 |
AU726630B2 (en) | 2000-11-16 |
DE69634960D1 (de) | 2005-08-25 |
NO320958B1 (no) | 2006-02-20 |
WO1997023238A1 (fr) | 1997-07-03 |
PT869814E (pt) | 2005-09-30 |
CA2240541C (en) | 2005-03-29 |
EP0869814B1 (fr) | 2005-07-20 |
ATE299712T1 (de) | 2005-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000502672A (ja) | 生ワクチンの安定化剤 | |
KR0149677B1 (ko) | 안정화된 생 백신 | |
AU2010304898B2 (en) | Stabilising excipient for inactivated whole-virus vaccines | |
US3755557A (en) | Spray vaccines | |
KR101960102B1 (ko) | 비강내 전달을 위한 방법 및 조성물 | |
JPH046689B2 (ja) | ||
RU2484847C2 (ru) | Лиофилизированный препарат, содержащий гриппозную вакцину, и способ его получения | |
JP2002512970A (ja) | 安定化したウィルス製剤 | |
KR910009346B1 (ko) | 안정화된 생 비루스 백신 및 그의 제조방법 | |
WO2010124428A1 (zh) | 一种不含明胶的疫苗冻干保护剂及其制备方法 | |
JP2002516850A (ja) | 凍結乾燥ワクチンの安定化剤 | |
JP2008525444A (ja) | ウイルス組成物の安定化 | |
JPS6314729A (ja) | 生ワクチン用改良安定剤、その製造法およびそれを含有するワクチン | |
JPH06234659A (ja) | 安定化生ワクチン | |
JP2643982B2 (ja) | 安定性のある凍結乾燥ヘルペスウイルス生ワクチン | |
KR102544928B1 (ko) | 아미노산을 유효성분으로 함유하는 동물용 백신 또는 진단용 항원의 안정성 증진용 조성물 및 이의 용도 | |
CN109432017B (zh) | 鸡痘耐热冻干保护剂及其应用 | |
CN117018177A (zh) | 冻干用狂犬病疫苗组合物及其制备方法和应用 | |
WO1992020375A1 (en) | Non-stinging measles-mumps-rubella vaccine composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070525 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070627 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070911 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070925 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101005 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111005 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111005 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121005 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121005 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131005 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |